DIRS.INFO The most relevant business & tech news

☆ European markets set for gains ahead of euro zone inflation data
▼ + stars: | 2024-03-01 | by ( Elliot Smith | ) www.cnbc.com time to read: +1 min

A TV presenter gets ready for the daily reporting from the floor of the German share price index DAX at the stock exchange in Frankfurt, Germany, November 15, 2023. LONDON — European markets are set to open higher on Friday to start the new trading month after a winning February, with euro zone inflation data due mid-morning. The European stock index notched an all-time high last month, powered by the 11 GRANOLAS large-cap stocks that made up half of the gains across the entire Stoxx 600. Focus will turn Friday to February's flash euro zone inflation reading, expected at 10 a.m. London time, with economists in a Reuters poll predicting the consumer price index rose 2.5% year on year, down from 2.8% in January. German consumer price inflation on Thursday came in line with forecasts at 2.7% year on year.

Persons: DAX Organizations: LONDON, GSK, Roche, ASML, Nestle, Novartis, Novo Nordisk, L'Oreal, LVMH, AstraZeneca, SAP, Sanofi, Focus, European Central Bank, ECB, Fed Locations: Frankfurt, Germany, London

☆ The 11 GRANOLAS stocks power Europe to record highs, drawing Magnificent Seven comparisons
▼ + stars: | 2024-02-27 | by ( Elliot Smith | ) www.cnbc.com time to read: +3 min

The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, January 19, 2024. Staff | ReutersOver the last 12 months, just 11 stocks made up half of the gains that powered the pan-European Stoxx 600 stock index to a record-high close on Friday. "From a Global point of view, the GRANOLAS have even outperformed the so-called Magnificent 7 over the past two years. Their (out)performance is even more impressive on a risk-adjusted basis: with a volatility 2x lower than for the Magnificent 7, the GRANOLAS help to boost the Sharpe ratio." "This suggests that, in Europe, nearly all revenue growth of the STOXX 600 will come from the GRANOLAS.

Persons: Goldman Sachs, Sanofi —, Goldman, Tim Hayes, Ned Davis, Hayes Organizations: Staff, Reuters, GSK, Roche, ASML, Nestle, Novartis, Novo Nordisk, L'Oreal, LVMH, AstraZeneca, SAP, Sanofi, Street, Ned, Ned Davis Research, CNBC Locations: Frankfurt, Germany, Europe

☆ Viking stock doubled Tuesday. Here's where the next moves in the obesity space could come from
▼ + stars: | 2024-02-27 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

VKTX YTD mountain Viking shares year to date Then, Viking shares more than doubled in trading on Tuesday, putting the stock on pace to report a more than 300% year-to-date gain, after the company said its GLP-1/GIP receptor agonist VK2735 hit all its primary goals in a phase 2 clinical trial. The Tema Cardiovascular and Metabolic ETF (HRTS) , which is up 12% year to date, owns Novo, Lilly and Viking. Still early days Some analysts and investors admit it is still very early days for obesity treatment and many questions remain to be answered. "We continue to expect above consensus growth in the space, as we are bullish on adoption from payers and broader obesity uptake," Meacham wrote. For obesity only, Lilly has already gained a 38% share, despite only being in the market for 13 weeks, he said.

Persons: Eli Lilly, Geoff Meacham, Meacham, Lilly, Yuri Khodjamirian, Khodjamirian, Jeff Jonas, Becton Dickinson, Novo, BofA's Meacham, What's, Tema's, it's, Gabelli's Jonas, he's, William Blair, Andy Hsieh, Hsieh Organizations: Novo Nordisk, Bank of America, Centers for Disease Control, Zealand Pharma, Viking Therapeutics, Zealand, Food and Drug Administration, Novo, Metabolic, Therapeutics, Pharmaceuticals, Rock, AstraZeneca, Roche, Gabelli Funds, FDA, Viking, Merck, Pfizer Locations: U.S, Tema, Novo Nordisk's, GLP, Lilly

☆ Meet the ‘Granolas,’ Europe’s answer to the Magnificent 7 stocks
▼ + stars: | 2024-02-27 | by ( Anna Cooban | ) edition.cnn.com time to read: +4 min

London CNN —The Magnificent 7 tech stocks have been a big part of the extraordinary US market rally. But there’s a rival group of companies powering European stocks to new heights with even better returns, by some measures. Dubbed the “Granolas,” those 11 companies accounted for 60% of the gains on Europe’s benchmark stock index over the past 12 months. They have even slightly outperformed the Magnificent 7 over a longer period, according to Goldman Sachs. Their standout performance has “raised the issue of concentration effects” in the region’s stock market, says Philip Lawlor, managing director of markets research at Wilshire Indexes.

Persons: London CNN —, Goldman Sachs, ASML, ” Goldman Sachs, Goldman Sachs, Guillaume Jaisson, Ozempic, ‘, Philip Lawlor, ” Lawlor Organizations: London CNN, GSK, Roche, Novartis, Novo Nordisk, L’Oréal, AstraZeneca, SAP, Sanofi, “, CNN, Danish, Wilshire Indexes, —, Deutsche Bank Locations: LVMH, Europe, France, Germany, Denmark, Switzerland, Netherlands, United Kingdom, United States

☆ Novo Nordisk and Eli Lilly rival soars 32% after promising weight-loss drug results
▼ + stars: | 2024-02-26 | by ( Jenni Reid | ) www.cnbc.com time to read: +1 min

Vials move along a conveyor at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Monday, June 12, 2023. Shares of Denmark's Zealand Pharma rocketed higher, after the company posted strong results from a trial of a liver disease treatment that has been touted as a potential competitor in the booming weight-loss drug market. The drug has "demonstrated efficacy" in people with obesity and is currently undergoing five Phase-3 trials in a clinical program for people who are overweight or obese. Analysts latched onto the drug's possible efficacity in obesity research following the latest test results, which indicated the safety of the top dosage used in that trial. Several other firms, including Eli Lilly, Roche and AstraZeneca, also seek to compete in the sector.

Persons: Ozempic, Eli Lilly, Roche Organizations: Novo Nordisk, pharma, Denmark's Zealand Pharma, U.S . Food, Drug Administration, Zealand Pharma, Nordisk, AstraZeneca Locations: Hillerod, Denmark, U.S, London, Danish

☆ David Roche: Market's expectation that AI will revolutionize productivity will 'run out of fizz'
▼ + stars: | 2024-02-26 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDavid Roche: Market's expectation that AI will revolutionize productivity will 'run out of fizz'David Roche, president and global strategist at Independent Strategy, says the market expects artificial intelligence to "revolutionize productivity" in the U.S. economy, but that narrative will eventually "run out of fizz."

Persons: David Roche Organizations: Independent Locations: U.S

☆ JPMorgan says buy this immunology stock primed to rally nearly 40%
▼ + stars: | 2024-02-20 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Immunovant could emerge as a key player in the autoimmune space, according to JPMorgan. The bank initiated coverage of the biotech stock at an overweight rating, also setting a price target of $51. That implies that shares of Immunovant could rally more than 37% from their Friday closing price of $37.13. Immunovant stock has slid 9% so far this quarter. IMVT YTD mountain IMVT YTD chart As a key catalyst, the analyst underscored Immunovant's stats as one of the key players using anti-neonatal Fc receptor technology, or anti-FcRn technology, to treat autoimmune diseases.

Persons: Brian Cheng, Graves, Cheng, — CNBC's Michael Bloom Organizations: JPMorgan, IMVT, Telavant, Merck, Prometheus Locations: Immunovant, IMVT, Roche

A medication used to treat asthma can now be used to help people with food allergies avoid severe reactions, the U.S. Food and Drug Administration said Friday. Xolair, the brand name for the drug omalizumab, became the first medication approved to reduce allergic reactions caused by accidental exposure to food triggers. An estimated 17 million people in the U.S. have the type of food allergies that can cause rapid, serious symptoms, including severe, whole-body reactions that are potentially deadly. Wood estimated that 25% to 50% of people with food allergies, particularly children and young adults, would elect to use Xolair. The drug has been used “off-label” to treat food allergies, said Dr. Ruchi Gupta, director of the Center for Food Allergy & Asthma Research at Northwestern University.

Persons: Xolair, ”, Robert Wood, Wood, Ruchi Gupta Organizations: U.S . Food, Drug Administration, Johns Hopkins Children’s Center, FDA, National Institutes of Health, Center for Food Allergy, Asthma Research, Northwestern University, drugmakers Novartis, Roche, Genentech, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: U.S

☆ Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
▼ + stars: | 2024-02-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +8 min

Victoria Klesty | ReutersThe insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments. The dominant weight loss drugmakers, Novo Nordisk and Eli Lilly , have said supply woes likely won't go away anytime soon, as the popularity of those medicines continues to soar. Some Wall Street analysts project that the weight loss drug market could be worth $100 billion by the end of the decade. But both Novo Nordisk and Eli Lilly gave updates on positive supply developments to investors over the last week. Other forms of weight loss drugs could helpAlternative forms of weight loss drugs could also help alleviate supply constraints in the future.

Persons: Victoria Klesty, Eli Lilly, Cantor Fitzgerald, Louise Chen, Nordisk's Wegovy, Eli Lilly's Zepbound, Goldman Sachs, Jeff Friedman, Novo, Mike Segar, Eli, Catalent, Yves Herman Yves Herman, TD Cowen, Michael Nedelcovych, Anat Ashkenazi, Cantor Fitzgerald's Chen, Morgan Stanley, Eli Lilly's, George Frey Organizations: Novo Nordisk, CNBC, Nordisk's, University of Florida, Pfizer, AstraZeneca, Roche, Food, Nordisk, Company, FDA, Novo Holdings, Wegovy, REUTERS, Reuters, U.S Locations: Oslo, Norway, Novo, U.S, Branchburg , New Jersey, Brussels, Belgium, Catalent, Concord , North Carolina, North, Germany, Indiana, Denmark, France

☆ Asset manager names one under-the-radar market to buy when times are bad, giving 6 stock picks
▼ + stars: | 2024-02-08 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +4 min

"People recommend investing in the Swiss market during uncertain periods – like if you are expecting a recession. "Maybe in a bull market, Swiss equities are not going to be a huge outperformer globally — but they can generate positive returns. But in difficult times, Swiss equities, besides the U.S., is one of the markets to buy," Bänziger said. In her view, Swiss stocks benefit from the strong Swiss franc and a political system that fosters innovation in companies. Meanwhile, Bänziger believes Swiss Prime Site and PSP Swiss Property make good investments among small- and mid-caps, given the opportunities in the Swiss real estate sector.

Persons: Carla Bänziger, Bänziger, Stocks Organizations: U.S . Federal, that's, CNBC Pro, Swiss, State Secretariat, Economic Affairs, Swiss Re, SIX Swiss Exchange, Dow Jones International Real, ABB, Nestle, Roche, Novartis Locations: that's Switzerland, Swiss, Zurich, U.S, Switzerland, Germany, China, Europe

☆ Startup funding is falling in most major cities. So why is Boston pulling ahead?
▼ + stars: | 2024-02-05 | by ( Melia Russell | Rebecca Torrence | ) www.businessinsider.com time to read: +8 min

AdvertisementThe Bay Area took the lion's share of capital raised on Carta in 2023, followed by Boston, then New York. AdvertisementAccording to Carta data, select metro areas saw the total early-stage funding raised decline by at least a third from 2022 to 2023. Yet early-stage funding was only down 24% in Boston, however, the smallest decrease of the metro areas that Carta tracks. According to Carta data, about $2.6 billion of capital raised in biotech flowed to Boston startups last year. Beyond biotechThe Carta data shows Boston also had strong showings across investment in software-as-a-service and hardware.

Persons: —, Zach Weinberg, Roche, Carta, Founders, that's, Rudina Seseri, Seseri, Peter Walker, Michael Greeley, Greeley, Mark Castleman, Castleman, Clement Cazalot, Cazalot, Walker Organizations: Service, Massachusetts Turnpike, Partners, Business, Carta, Boston, East Coast, Companies, Area, Flare Capital Partners, pharma, Intel Ignite, Glasswing Ventures, Founders, Machinery, Pritzker Group, Armory Square Ventures, Way Ventures, Klaviyo's, New York Stock Exchange Locations: Boston, New York City, East, Boston , Cambridge, Newton , Massachusetts, Newark, Jersey City , New Jersey, New York, San Francisco, Bay, France, Copley

☆ The inventor of Wall Street's favorite recession indicator predicts a slowdown this year - and slams the Fed for making things worse
▼ + stars: | 2024-01-26 | by ( Theron Mohamed | ) www.businessinsider.com time to read: +3 min

"The model is forecasting lower economic growth in 2024 and I believe that will be realized," Harvey said, predicting a slowdown this quarter that will continue into the summer. AdvertisementHarvey also called on the Fed to end its inflation fight, arguing price growth has already normalized based on real-time housing data. "What the Fed has done in this cycle has made things worse, so we will be very fortunate to get out of this with slow growth." That could slow economic growth in the short term but prevent a full-blown recession later, he said. On the other hand, he argued the US should aim to accelerate economic growth to 5% by capitalizing on innovations like artificial intelligence and decentralized finance.

Persons: Campbell Harvey, Julia Roche, Harvey, hasn't, it's Organizations: Service, Federal, Business, Duke University, Fed

Publicly listed data company LiveRamp's $200 million acquisition of data clean room provider Habu looks set to fire the starting pistol for a more buoyant year of adtech and martech M&A, experts have predicted. He noted that while ad teams aren't using these clean rooms en masse, many have activated them, which bodes well for the Habu acquisition. ID5's technology is deployed by the most online publishers of any identity service, according to Sincera , which measures which adtech companies are used across the industry. LiveRamp, also, could be an acquisition target, Salmon noted, as it builds out new data offerings like the clean rooms it will inherit from Habu. But not everyone is predicting the Habu acquisition will necessarily lead to an influx of M&A around cookieless adtech.

Persons: Conor McKenna, Luma's McKenna, Shailin Dhar, Dhar, Mathieu Roche, who've, InfoSum, Myles Younger, Dan Salmon, Wayne Blodwell, ID5, Roche, " Roche, Salmon, Elgin Thompson, hasn't, Thompson Organizations: Business, LUMA Partners, FIT Holdings, Companies, New, Research, Impact Media, Citizens JMP Securities, Walmart Locations: adtech, LiveRamp, Habu

☆ David Roche discusses Taiwan election results and China relations
▼ + stars: | 2024-01-15 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTaiwan's election shows 'absolutely no support' for reunification with China, says David RocheDavid Roche, global strategist at Independent Strategy, discusses Taiwan's election results and relations with China.

Persons: David Roche David Roche Organizations: Independent Locations: China

☆ Veteran investor David Roche says the market is getting it wrong on Taiwan's election result
▼ + stars: | 2024-01-15 | by ( Elliot Smith | ) www.cnbc.com time to read: +4 min

Taiwan's President Tsai Ing-wen speaks as Lai Ching-te, Taiwan's vice president and the ruling Democratic Progressive Party's (DPP) presidential candidate looks on during a campaign rally ahead of the elections in Taipei, Taiwan, January 11, 2024. Carlos Garcia Rawlins | ReutersTaiwan's election results place the island on a "collision course with China" and the market reaction has been too sanguine, according to veteran investor David Roche. Beijing has already dismissed the outcome of Saturday's elections, which saw the ruling Democratic Progressive Party's Lai Ching-te elected president alongside a split parliamentary vote. The DPP rejects the so-called "One China principle" and advocates a separate and distinct Taiwanese national identity. Xi has repeatedly stated that Taiwan will be reunified with China, and has not ruled out using military force to achieve his goals.

Persons: Tsai Ing, Lai Ching, Democratic Progressive Party's, Carlos Garcia Rawlins, David Roche, Party's Lai Ching, Roche, CNBC's, Lai, Xi Jinping, Xi Organizations: Democratic Progressive, Reuters, Democratic, DPP, Independent, CSI, Chinese Communist Party, Citi, KMT Locations: Taipei, Taiwan, China, Beijing

☆ 4 stock ideas I brought back from the JPMorgan Healthcare Conference and everything else I learned about the industry
▼ + stars: | 2024-01-15 | by ( Jim Cramer | ) www.cnbc.com time to read: +12 min

We will go over them – but first, let me talk about what I learned at last week's JPMorgan Health Care Conference that I attended in San Francisco, and what it means to your portfolio. We know health care has a lot of angles too it. The previous CEO Roz Brewer was from Starbucks and struggled with the role that Walgreens plays in health care. You have to be following the transformation of Bristol-Myers, which is opening its wallet to buy a host of drug companies, including anti-psychotic firm Karuna. Health care is the way to go.

Persons: Regeneron, Pfizer, Eli Lilly, Dave Ricks, Lilly, donanemab, Lilly's, Zepbound, it's, Abbott, It's, Roche, Merck, Myers, ABT, Robert Ford, Tim Wentworth, He's, Roz Brewer, Wentworth, he'll, Brewer wasn't, Bob Bradway, Amgen, Vas Narasimhan, Sandoz, Karuna, Medtronic, Hugo, Morgan Stanley, Wells, Covid, Cramer's, Jim Cramer, Jim, Las Vegas Brendan Smialowski Organizations: Abbott Labs, Covid, Novartis, Amgen, Walgreens Boots Alliance, JPMorgan Health Care Conference, Humana, Drug Administration, Novo Nordisk, Dickinson Co, Bristol, Myers Squibb, Pfizer, Department, WBA, Walgreens, Starbucks, -, pharma, Merck, Keytruda, Horizon Therapeutics, Federal Trade Commission, Myers, BD, CVS Health, JPMorgan, Cramer's Charitable, CNBC, Consumer, AFP, Getty Locations: San Francisco, GLP, North Carolina, Europe, Cencora, Amgen, West, Bristol, Target, Las Vegas

☆ AI Davids ride coattails of industry Goliaths
▼ + stars: | 2023-12-05 | by ( ) www.reuters.com time to read: +2 min

New York, Dec 5 (Reuters Breakingviews) - Artificial intelligence Goliaths like OpenAI continue to open the door for what might become the industry’s Davids. With a low-cost approach and data privacy focus, it may be able to eventually carve out a solid European business. Mistral has whiffs of what OpenAI, eyeing a mooted $86 billion valuation and eight years old, once was, but with tweaks. Mistral has also focused on “open sourcing” its models, which means they can be downloaded and used for free. As a Paris-based company, Mistral could build out its business with a specific focus on complying with AI rules being finalized by the European Union.

Persons: industry’s Davids, eyeing, Anita Ramaswamy, Neiman Marcus, Lauren Silva Laughlin, Aditya Sriwatsav Organizations: Reuters, Mistral, Bloomberg, European Union, X, Saks, Thomson Locations: York, Paris, Kuwait, Hong Kong

☆ Fed is 'disconnected' from reality, must cut rates 5 times next year, portfolio manager says
▼ + stars: | 2023-12-05 | by ( Shreyashi Sanyal | ) www.cnbc.com time to read: +3 min

Chris Wattie | ReutersThe Federal Reserve needs to cut interest rates at least five times next year to avoid tipping the U.S. economy into a recession, according to portfolio manager Paul Gambles. "I think Fed policy is now so disconnected from economic factors and from reality that you can't make any assumptions about when the Fed is going to wake up and and start smelling the amount of damage that they're actually causing to the economy," Gambles warned. The current U.S. policy rate stands at 5.25%-5.50%, the highest in 22 years. Traders are now pricing in a 25-basis-point cut as early as March 2024, according to the CME FedWatch Tool. The perception now being that the U.S. central bank is effectively done raising interest rates.

Persons: Chris Wattie, Paul Gambles, CNBC's, Gambles, Jerome Powell, Powell, Wall, David Roche, Roche Organizations: Reuters, Federal Reserve, MBMG, Traders, Federal, Financial, Labor Locations: U.S

☆ Kuwait rings up small bill in tower merger
▼ + stars: | 2023-12-05 | by ( ) www.reuters.com time to read: +2 min

A three-way partnership deal will enable Qatar’s Ooredoo (ORDS.QA) to offload capital-intensive infrastructure but only by offering Kuwait’s Zain (ZAIN.KW) favourable deal terms. Ooredoo and Zain are creating a regional powerhouse with an estimated enterprise value of $2.2 billion to be managed by Zain-backed TASC Towers Holding. The $8.9 billion Ooredoo and $6.9 billion Zain will own 49.3% each, with the rest going to TASC. But Zain is paying an average price of $73,000 per tower, 9.5% less than the average price per tower in previous deals, according to JPMorgan analysts. The Kuwaiti group will also call the shots as the founders of Dubai’s TASC Towers Holding – which Zain controls with an 83.47% stake – will manage the new entity.

Persons: Qatar’s, Kuwait’s Zain, Zain, Ooredoo, Dubai’s, Pamela Barbaglia, Neiman Marcus, Francesco Guerrera, Oliver Taslic Organizations: Reuters, TASC, Bloomberg, JPMorgan, X, Saks, Thomson Locations: Algeria, Tunisia, Iraq, Jordan, Saudi, Kuwaiti, Hong Kong

☆ David Roche says U.S. inflation won't reach 2%
▼ + stars: | 2023-12-04 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDavid Roche says U.S. inflation won't reach 2%David Roche of Independent Strategy says it's clear that the U.S. Federal Reserve is done raising interest rates, "which means the next move is down."

Persons: David Roche Organizations: U.S . Federal

☆ Roche enters obesity market with Carmot takeover but drugs may not be available until 2030
▼ + stars: | 2023-12-04 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +1 min

BRAZIL - 2021/11/26: In this photo illustration a F. HoffmannLa Roche AG logo is seen on a screen and a hand holding a pill. (Photo Illustration by Rafael Henrique/SOPA Images/LightRocket via Getty Images)Swiss pharmaceuticals giant Roche is set to acquire anti obesity drug developer Carmot Therapeutics, becoming the latest company to attempt to unseat Novo Nordisk and Eli Lilly's dominance within the global weight-loss drugs market. The U.S. takeover target's early-stage technology could help crack highly prized oral obesity treatments, Roche Pharmaceuticals CEO Teresa Graham said Monday, but it may be several years before the drugs are widely available. The deal will provide Roche access to Carmot's current research and development portfolio, including all clinical and preclinical assets. Shares of the Swiss company, which have been in the doldrums this year, were up 2.25% following the news of the acquisition.

Persons: HoffmannLa Roche, Rafael Henrique, Roche, Eli Lilly's, Teresa Graham, we'll, Graham, CNBC's Julianna Tatelbaum, Eli Lilly's Mounjaro Organizations: Getty Images, Carmot Therapeutics, Novo Nordisk, U.S, Roche Pharmaceuticals, Roche Locations: BRAZIL, Swiss, California

☆ Roche’s late obesity punt offers wider market cure
▼ + stars: | 2023-12-04 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Arnd Wiegmann Acquire Licensing RightsLONDON, Dec 4 (Reuters Breakingviews) - Roche’s (ROG.S) foray into the prospective $100 billion obesity market can bring wider benefits. On Monday, the $224 billion Swiss pharma group said it had agreed to take over weight-loss drug developer Carmot Therapeutics for $2.7 billion. Market leader Novo Nordisk (NOVOb.CO) is already selling obesity drugs in the U.S. and parts of Europe. Still, Schinecker’s obesity bet could turn successful if it ends up undercutting obesity pioneers on prices. With over 1 billion people globally classed as seriously overweight, other drugmakers will follow Roche on the obesity bandwagon.

Persons: drugmaker Roche, Arnd, Eli Lilly’s, Thomas Schinecker, Eli Lilly, Eccogene, Roche, Aimee Donnellan, Neiman Marcus, Lisa Jucca, Oliver Taslic Organizations: REUTERS, Reuters, Swiss pharma, Carmot Therapeutics, Novo Nordisk, U.S . Food, Drug Administration, AstraZeneca, Novo, X, Saks, Thomson Locations: Basel, Switzerland, U.S, Europe, Hong Kong

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing RightsZURICH, Dec 4 (Reuters) - Roche (ROG.S) agreed to take over obesity drug developer Carmot Therapeutics (CRMO.O) for $2.7 billion, joining a list global contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk (NOVOb.CO) and Eli Lilly. After encouraging Phase I trial results, the drug is ready to be tested on humans in the second of three trial stages, Roche added. Among recent deals to acquire obesity drug development projects, AstraZeneca (AZN.L) last month agreed to pay up to $2 billion for the rights to an experimental pill from China's Eccogene. Roche will obtain access to Carmot's current R&D portfolio including all clinical and preclinical assets.

Persons: drugmaker Roche, Arnd, ROG.S, Eli Lilly, Swiss drugmaker, Roche, . New Roche, Thomas Schinecker, Ludwig Burger, Noel Illien, Rachel More, Louise Heavens Organizations: REUTERS, Rights, Carmot Therapeutics, Novo Nordisk, AstraZeneca, Pfizer, Thomson Locations: Basel, Switzerland, Swiss, ., Alzheimer's

☆ Chipmaker Analog Devices' forecasts held back by inventory corrections
▼ + stars: | 2023-11-21 | by ( ) www.reuters.com time to read: +2 min

Analog Devices' logo is pictured on a smartphone in this illustration taken, December 4, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing RightsNov 21 (Reuters) - Chipmaker Analog Devices (ADI.O) projected first-quarter revenue and profit below market estimates on Tuesday, as it grapples with the ongoing supply glut in the semiconductor industry. Inflation-hit customers have refrained from placing new orders for chips, leading to excess supply at companies such as Analog Devices after a pandemic-driven buying spree fizzled out. First-quarter adjusted earnings are expected to be $1.70 per share, plus or minus 10 cents, below analysts' average estimates of $1.90. Cautious spending by automakers fearing a slowdown in their electric-vehicle businesses has also weighed on orders at Analog Devices.

Persons: Dado Ruvic, Vincent Roche, Arsheeya, Tasim Zahid Organizations: REUTERS, Texas, Analog Devices, Thomson Locations: Bengaluru

☆ Stocks may crash 30%, a recession looks imminent, and commercial real estate is a bubble about to burst, market prophet says. Here are Gary Shilling's 8 best quotes from a new interview.
▼ + stars: | 2023-11-19 | by ( Theron Mohamed | ) www.businessinsider.com time to read: +4 min

Market prophet Gary Shilling issued a raft of dire warnings to investors in an interview this week. Stocks may crash 30%, a recession is imminent, and commercial real estate is a bubble about to burst, he said. AdvertisementStocks could crater by 30%, the US economy is careening toward recession, and commercial real estate is a bubble about to burst, a legendary market prophet warned this week. "I think the biggest bubble right now is commercial real estate. This isn't of the magnitude of the subprime-mortgage bonanza, but I think it is a bubble which is beginning to crack."

Persons: Gary Shilling, Shilling, —, Julia La Roche, I've, they've, we're, John Paulson Organizations: Service, Federal Reserve

Search resuls for: "roche"

25 mentions found